Axogen to acquire BioCircuit Technologies for $200m cash

Axogen (Nasdaq: AXGN), the Florida-based peripheral nerve repair specialist, has signed a definitive agreement to acquire privately held BioCircuit Technologies for $200 million in cash. The deal adds NerveTape, which the company describes as the first FDA-approved device for sutureless peripheral nerve repair, to a portfolio that already includes nerve grafts, connectors, and protectors.

The transaction is expected to close in the fourth quarter of 2026, subject to customary conditions including a spin-out of BioCircuit's electronics research and development business prior to closing. Axogen intends to fund the purchase price from the net proceeds of a concurrent public equity offering announced on the same day. BofA Securities is advising Axogen; Piper Sandler is advising BioCircuit.

The deal rationale

NerveTape works by allowing surgeons to align, connect and protect a transected nerve without relying on microsutures, a technically demanding technique that constrains which surgeons can perform nerve repair and in which settings. Axogen argues that removing the microsurgical dependency broadens both the pool of eligible surgeons and the range of care settings where the procedure can take place.

Michael Dale, President and Chief Executive of Axogen, said the technology "makes high-quality nerve repair simpler and more accessible for surgeons" and advances the company's stated ambition to make restoration of peripheral nerve function a routine standard of care. BioCircuit chief executive Michelle Jarrard highlighted Axogen's commercial infrastructure, reimbursement expertise and existing surgeon relationships as the main rationale for the combination from her company's perspective.

Axogen is guiding for the acquisition to be accretive to revenue growth, adjusted EBITDA margin and adjusted earnings per share in the first full year following close, while maintaining positive free cash flow. Full-year 2027 financial guidance incorporating BioCircuit will be provided in the first quarter of next year.

Market context

Peripheral nerve repair is a relatively concentrated medical device segment dominated by a handful of specialists. Axogen has been the most visible pure-play in the space, with its Avance nerve allograft franchise forming the core of its commercial business. Adding a sutureless repair platform is consistent with a broader industry trend toward simplifying technically complex surgical procedures, a dynamic that has driven adoption in adjacent fields such as anastomosis and wound closure.

BioCircuit was backed by National Institutes of Health small-business funding alongside private investors including Alsora Capital and GRA Venture Fund, reflecting the early-stage, grant-supported development path common to surgical-device innovators targeting niche indications. The electronics and bioelectronics capabilities being spun out prior to closing suggest BioCircuit was pursuing a neuromodulation research agenda beyond nerve repair, which Axogen has chosen not to acquire.

For investors, the key questions will be how quickly Axogen can convert its existing surgeon relationships into NerveTape adoption, and whether the technology's performance profile holds up as use expands beyond the controlled early-adopter cohort. Clinical experience data referenced in the release was not quantified, and independent peer-reviewed evidence will be important to watch as the integration progresses.